Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsInvestigators demonstrated that MYCN–amplified neuroblastomas were sensitive to the combined inhibition of MCT1 and complex I of the mitochondrion.
[Proceedings of the National Academy of Sciences of the United States of America]
6807162 K2KTYWVM items 1 apa 0 default asc 1 160566 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-e3afd6da33684cb04956a836086a0a5b%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22K2KTYWVM%22%2C%22library%22%3A%7B%22id%22%3A6807162%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dalton%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-30%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDalton%2C%20K.%20M.%2C%20Lochmann%2C%20T.%20L.%2C%20Floros%2C%20K.%20V.%2C%20Calbert%2C%20M.%20L.%2C%20Kurupi%2C%20R.%2C%20Stein%2C%20G.%20T.%2C%20McClanaghan%2C%20J.%2C%20Murchie%2C%20E.%2C%20Egan%2C%20R.%20K.%2C%20Greninger%2C%20P.%2C%20Dozmorov%2C%20M.%2C%20Ramamoorthy%2C%20S.%2C%20Puchalapalli%2C%20M.%2C%20Hu%2C%20B.%2C%20Shock%2C%20L.%2C%20Koblinski%2C%20J.%2C%20Glod%2C%20J.%2C%20Boikos%2C%20S.%20A.%2C%20Benes%2C%20C.%20H.%2C%20%26amp%3B%20Faber%2C%20A.%20C.%20%282021%29.%20Catastrophic%20ATP%20loss%20underlies%20a%20metabolic%20combination%20therapy%20tailored%20for%20MYCN-amplified%20neuroblastoma.%20%3Ci%3EProceedings%20of%20the%20National%20Academy%20of%20Sciences%3C%5C%2Fi%3E%2C%20%3Ci%3E118%3C%5C%2Fi%3E%2813%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.2009620118%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1073%5C%2Fpnas.2009620118%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6807162%26amp%3Bitem_key%3DK2KTYWVM%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Catastrophic%20ATP%20loss%20underlies%20a%20metabolic%20combination%20therapy%20tailored%20for%20MYCN-amplified%20neuroblastoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krista%20M.%22%2C%22lastName%22%3A%22Dalton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20L.%22%2C%22lastName%22%3A%22Lochmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Konstantinos%20V.%22%2C%22lastName%22%3A%22Floros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marissa%20L.%22%2C%22lastName%22%3A%22Calbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Kurupi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanna%20T.%22%2C%22lastName%22%3A%22Stein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22McClanaghan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Murchie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%20K.%22%2C%22lastName%22%3A%22Egan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Greninger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikhail%22%2C%22lastName%22%3A%22Dozmorov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sivapriya%22%2C%22lastName%22%3A%22Ramamoorthy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madhavi%22%2C%22lastName%22%3A%22Puchalapalli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bin%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Shock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Koblinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Glod%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sosipatros%20A.%22%2C%22lastName%22%3A%22Boikos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%20H.%22%2C%22lastName%22%3A%22Benes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20C.%22%2C%22lastName%22%3A%22Faber%22%7D%5D%2C%22abstractNote%22%3A%22MYCN-amplified%20neuroblastoma%20is%20a%20lethal%20subset%20of%20pediatric%20cancer.%20MYCN%20drives%20numerous%20effects%20in%20the%20cell%2C%20including%20metabolic%20changes%20that%20are%20critical%20for%20oncogenesis.%20The%20understanding%20that%20both%20compensatory%20pathways%20and%20intrinsic%20redundancy%20in%20cell%20systems%20exists%20implies%20that%20the%20use%20of%20combination%20therapies%20for%20effective%20and%20durable%20responses%20is%20necessary.%20Additionally%2C%20the%20most%20effective%20targeted%20therapies%20exploit%20an%20%5Cu201cAchilles%5Cu2019%20heel%5Cu201d%20and%20are%20tailored%20to%20the%20genetics%20of%20the%20cancer%20under%20study.%20We%20performed%20an%20unbiased%20screen%20on%20select%20metabolic%20targeted%20therapy%20combinations%20and%20correlated%20sensitivity%20with%20over%2020%20subsets%20of%20cancer.%20We%20found%20that%20MYCN-amplified%20neuroblastoma%20is%20hypersensitive%20to%20the%20combination%20of%20an%20inhibitor%20of%20the%20lactate%20transporter%20MCT1%2C%20AZD3965%2C%20and%20complex%20I%20of%20the%20mitochondrion%2C%20phenformin.%20Our%20data%20demonstrate%20that%20MCT4%20is%20highly%20correlated%20with%20resistance%20to%20the%20combination%20in%20the%20screen%20and%20lowly%20expressed%20in%20MYCN-amplified%20neuroblastoma.%20Low%20MCT4%20combines%20with%20high%20expression%20of%20the%20MCT2%20and%20MCT1%20chaperone%20CD147%20in%20MYCN-amplified%20neuroblastoma%2C%20altogether%20conferring%20sensitivity%20to%20the%20AZD3965%20and%20phenformin%20combination.%20The%20result%20is%20simultaneous%20disruption%20of%20glycolysis%20and%20oxidative%20phosphorylation%2C%20resulting%20in%20dramatic%20disruption%20of%20adenosine%20triphosphate%20%28ATP%29%20production%2C%20endoplasmic%20reticulum%20stress%2C%20and%20cell%20death.%20In%20mouse%20models%20of%20MYCN-amplified%20neuroblastoma%2C%20the%20combination%20was%20tolerable%20at%20concentrations%20where%20it%20shrank%20tumors%20and%20did%20not%20increase%20white-blood-cell%20toxicity%20compared%20to%20single%20drugs.%20Therefore%2C%20we%20demonstrate%20that%20a%20metabolic%20combination%20screen%20can%20identify%20vulnerabilities%20in%20subsets%20of%20cancer%20and%20put%20forth%20a%20metabolic%20combination%20therapy%20tailored%20for%20MYCN-amplified%20neuroblastoma%20that%20demonstrates%20efficacy%20and%20tolerability%20in%20vivo.%5CnAuthor%20Information%5CnKrista%20M.%20Daltona%2C%20Timothy%20L.%20Lochmanna%2C%20Konstantinos%20V.%20Florosa%2C%20Marissa%20L.%20Calberta%2C%20Richard%20Kurupia%2C%20Giovanna%20T.%20Steinb%2Cc%2C%20Joseph%20McClanaghanb%2Cc%2C%20Ellen%20Murchieb%2Cc%2C%20Regina%20K.%20Eganb%2Cc%2C%20Patricia%20Greningerb%2Cc%2C%20Mikhail%20Dozmorovd%2C%20Sivapriya%20Ramamoorthye%2C%20Madhavi%20Puchalapallif%2C%20Bin%20Huf%2C%20Lisa%20Shockg%2C%20Jennifer%20Koblinskif%2C%20John%20Glodh%2C%20Sosipatros%20A.%20Boikosi%2C%20Cyril%20H.%20Benesb%2Cc%2C1%2C%20and%20Anthony%20C.%20Fabera%2C1aPhilips%20Institute%20for%20Oral%20Health%20Research%2C%20VCU%20School%20of%20Dentistry%20and%20Massey%20Cancer%20Center%2C%20Virginia%20Commonwealth%20University%2C%20Richmond%2C%20VA%2023298%3BbCenter%20for%20Cancer%20Research%2C%20Massachusetts%20General%20Hospital%20Cancer%20Center%2C%20Boston%2C%20MA%2002129%3BcDepartment%20of%20Medicine%2C%20Harvard%20Medical%20School%2C%20Boston%2C%20MA%2002115%3BdDepartment%20of%20Biostatistics%2C%20Virginia%20Commonwealth%20University%2C%20Richmond%2C%20VA%2023298%3BeDiscovery%20and%20Translational%20Sciences%2C%20Metabolon%2C%20Inc.%2C%20Research%20Triangle%20Park%2C%20NC%2027709%3BfDepartment%20of%20Pathology%2C%20Virginia%20Commonwealth%20University%2C%20Richmond%2C%20VA%2023298%3BgDepartment%20of%20Microbiology%20and%20Immunology%2C%20Virginia%20Commonwealth%20University%2C%20Richmond%2C%20VA%2023298%3BhPediatric%20Oncology%20Branch%2C%20National%20Cancer%20Institute%2C%20National%20Institutes%20of%20Health%2C%20Bethesda%2C%20MD%2020892%3BiDepartment%20of%20Internal%20Medicine%2C%20Virginia%20Commonwealth%20University%2C%20Richmond%2C%20VA%2023298Edited%20by%20Robert%20N.%20Eisenman%2C%20Fred%20Hutchinson%20Cancer%20Research%20Center%2C%20Seattle%2C%20WA%2C%20and%20approved%20January%2022%2C%202021%20%28received%20for%20review%20May%2019%2C%202020%29%5CnFootnotes%5Cu21b51To%20whom%20correspondence%20may%20be%20addressed.%20Email%3A%20cyrilbenes%40gmail.com%20or%20acfaber%40vcu.edu.Author%20contributions%3A%20C.H.B.%20and%20A.C.F.%20designed%20research%3B%20K.M.D.%2C%20T.L.L.%2C%20K.V.F.%2C%20M.L.C.%2C%20R.K.%2C%20G.T.S.%2C%20J.M.%2C%20E.M.%2C%20R.K.E.%2C%20S.R.%2C%20M.P.%2C%20and%20B.H.%20performed%20research%3B%20M.D.%20and%20L.S.%20contributed%20new%20reagents%5C%2Fanalytic%20tools%3B%20K.M.D.%2C%20T.L.L.%2C%20P.G.%2C%20M.D.%2C%20S.R.%2C%20L.S.%2C%20J.K.%2C%20J.G.%2C%20S.A.B.%2C%20C.H.B.%2C%20and%20A.C.F.%20analyzed%20data%3B%20K.M.D.%2C%20T.L.L.%2C%20M.D.%2C%20L.S.%2C%20J.K.%2C%20J.G.%2C%20S.A.B.%2C%20C.H.B.%2C%20and%20A.C.F.%20contributed%20to%20the%20interpretation%20of%20results%20and%20provided%20critical%20feedback%3B%20and%20K.M.D.%2C%20T.L.L.%2C%20C.H.B.%2C%20and%20A.C.F.%20wrote%20the%20paper.Competing%20interest%20statement%3A%20The%20work%20in%20the%20laboratory%20of%20C.H.B.%20is%20funded%20in%20part%20by%20Amgen%20and%20Novartis.%20A.C.F.%20has%20served%20as%20a%20paid%20consultant%20for%20AbbVie.%20Amgen%2C%20Novartis%2C%20and%20AbbVie%20had%20no%20role%20in%20the%20conceptualization%2C%20study%20design%2C%20data%20collection%20and%20analysis%2C%20decision%20to%20publish%2C%20or%20preparation%20of%20the%20manuscript.This%20article%20is%20a%20PNAS%20Direct%20Submission.This%20article%20contains%20supporting%20information%20online%20at%20https%3A%5C%2F%5C%2Fwww.pnas.org%5C%2Flookup%5C%2Fsuppl%5C%2Fdoi%3A10.1073%5C%2Fpnas.2009620118%5C%2F-%5C%2FDCSupplemental.%22%2C%22date%22%3A%222021%5C%2F03%5C%2F30%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1073%5C%2Fpnas.2009620118%22%2C%22ISSN%22%3A%220027-8424%2C%201091-6490%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.pnas.org%5C%2Fcontent%5C%2F118%5C%2F13%5C%2Fe2009620118%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-03-26T18%3A59%3A46Z%22%7D%7D%5D%7D
Dalton, K. M., Lochmann, T. L., Floros, K. V., Calbert, M. L., Kurupi, R., Stein, G. T., McClanaghan, J., Murchie, E., Egan, R. K., Greninger, P., Dozmorov, M., Ramamoorthy, S., Puchalapalli, M., Hu, B., Shock, L., Koblinski, J., Glod, J., Boikos, S. A., Benes, C. H., & Faber, A. C. (2021). Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma. Proceedings of the National Academy of Sciences, 118(13). https://doi.org/10.1073/pnas.2009620118 Cite
